Preclinical CRO Market (By Service: Toxicology Testing, Bioanalysis & DMPK Studies, Chemistry, Compound Management, Safety Pharmacology, and Others; End Use: Medical Device Companies, Biopharmaceutical, and Government & Academic Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024 - 2033
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Preclinical CRO Market
5.1. COVID-19 Landscape: Preclinical CRO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Preclinical CRO Market, By Service
8.1. Preclinical CRO Market, by Service Type, 2024-2033
8.1.1. Toxicology Testing
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Bioanalysis & DMPK Studies
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Chemistry
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Compound Management
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Safety Pharmacology
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Preclinical CRO Market, By End Use
9.1. Preclinical CRO Market, by End Use, 2024-2033
9.1.1. Medical Device Companies
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Biopharmaceutical
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Government & Academic Institutes
9.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Preclinical CRO Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Service (2021-2033)
10.1.2. Market Revenue and Forecast, by End Use (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.1.3.2. Market Revenue and Forecast, by End Use (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.1.4.2. Market Revenue and Forecast, by End Use (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.2. Market Revenue and Forecast, by End Use (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.3.2. Market Revenue and Forecast, by End Use (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.4.2. Market Revenue and Forecast, by End Use (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.5.2. Market Revenue and Forecast, by End Use (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.6.2. Market Revenue and Forecast, by End Use (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.2. Market Revenue and Forecast, by End Use (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.3.2. Market Revenue and Forecast, by End Use (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.4.2. Market Revenue and Forecast, by End Use (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.5.2. Market Revenue and Forecast, by End Use (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.6.2. Market Revenue and Forecast, by End Use (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.2. Market Revenue and Forecast, by End Use (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.3.2. Market Revenue and Forecast, by End Use (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.4.2. Market Revenue and Forecast, by End Use (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.5.2. Market Revenue and Forecast, by End Use (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.6.2. Market Revenue and Forecast, by End Use (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Service (2021-2033)
10.5.2. Market Revenue and Forecast, by End Use (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.5.3.2. Market Revenue and Forecast, by End Use (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.5.4.2. Market Revenue and Forecast, by End Use (2021-2033)
Chapter 11. Company Profiles
11.1. Wuxi AppTec
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Pharmaceutical Product Development
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Medpace, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Charles River Laboratories International, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. PRA Health Science, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. PAREXEL
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Envigo
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Eurofins Scientific.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Laboratory Corporation of America
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. ICON Plc
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample